Details of the Drug
General Information of Drug (ID: DMJD0UV)
Drug Name |
3-Hydroxy-3-Methyl-Glutaric Acid
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Meglutol; MEGLUTOL; 3-Hydroxy-3-methylglutaric acid; 503-49-1; Dicrotalic acid; 3-Hydroxy-3-methylpentanedioic acid; Lipoglutaren; Medroglutaric acid; 3-hydroxy-3-methyl-glutaric acid; HMGA; beta-Hydroxy-beta-methylglutaric acid; Meglutolum; Meglutol [USAN:INN]; Meglutolum [INN-Latin]; Pentanedioic acid, 3-hydroxy-3-methyl-; CB-337; CB 337; UNII-CLA99KCD53; 3-Hydroxy-3-methylglutarate; Glutaric acid, 3-hydroxy-3-methyl-; EINECS 207-971-1; NSC 361411; 3-Hydroxymethylglutaric acid; BRN 1769194; CLA99KCD53; CHEMBL50444; CHEBI:16831
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 162.14 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | -1.2 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 3 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 5 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||